CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

PacritinibWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1416 Infusion placebo Wiki 1.00
drug762 Convalescent anti-SARS-CoV-2 plasma Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D011024 Pneumonia, Viral NIH 0.12
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer

This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.

NCT04404361 COVID Drug: Pacritinib Drug: Placebo

Primary Outcomes

Description: The proportion is calculated as the number of patients who progress divided by the total number of patients in the ITT population.

Measure: Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization

Time: 28 days

No related HPO nodes (Using clinical trials)